{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:52:58Z","timestamp":1761555178568,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.cct.2019.105846","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T18:54:27Z","timestamp":1568228067000},"page":"105846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interim monitoring in a treatment strategy trial with a composite primary endpoint"],"prefix":"10.1016","volume":"86","author":[{"given":"Minhee","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Grund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Hunsberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Glidden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Volberding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2019.105846_bb0005","series-title":"Data Monitoring in Clinical Trials: A Case Studies Approach","first-page":"374","author":"DeMets","year":"2006"},{"year":"2002","series-title":"Data Monitoring Committees in Clinical Trials: A Practical Perspective","author":"Ellenberg","key":"10.1016\/j.cct.2019.105846_bb0010"},{"issue":"4","key":"10.1016\/j.cct.2019.105846_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/PCC.0b013e318274568c","article-title":"The role of the data and safety monitoring board in a clinical trial: the CRISIS study","volume":"14","author":"Holubkov","year":"2013","journal-title":"Pediatr. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.cct.2019.105846_bb0020","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/1740774515591498","article-title":"Developing training for data safety monitoring board members: a National Institute of Allergy and Infectious Diseases case study","volume":"12","author":"Zuckerman","year":"2015","journal-title":"Clin. Trials"},{"issue":"1","key":"10.1016\/j.cct.2019.105846_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1740774509356117","article-title":"Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field","volume":"7","author":"Wittkop","year":"2010","journal-title":"Clin. Trials"},{"issue":"27","key":"10.1016\/j.cct.2019.105846_bb0030","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/sim.6205","article-title":"Use of composite endpoints in clinical trials","volume":"33","author":"Sankoh","year":"2014","journal-title":"Stat. Med."},{"author":"FDA","key":"10.1016\/j.cct.2019.105846_bb0035"},{"issue":"5","key":"10.1016\/j.cct.2019.105846_bb0040","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/sim.5547","article-title":"Statistical considerations when using a composite endpoint for comparing treatment groups","volume":"32","author":"Gomez","year":"2013","journal-title":"Stat. Med."},{"issue":"28","key":"10.1016\/j.cct.2019.105846_bb0045","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1002\/sim.7386","article-title":"Composite and multicomponent end points in clinical trials","volume":"36","author":"Sankoh","year":"2017","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.cct.2019.105846_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0197-2456(00)00126-4","article-title":"ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1","volume":"22","author":"Smeaton","year":"2001","journal-title":"Control. Clin. Trials"},{"issue":"25","key":"10.1016\/j.cct.2019.105846_bb0055","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cct.2019.105846_bb0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.cct.2019.105846_bb0065","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cct.2019.105846_bb0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9747","key":"10.1016\/j.cct.2019.105846_bb0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cct.2019.105846_bb0080","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2019.105846_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cid\/ciy044","article-title":"As-needed Vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264\/AMC-067 randomized clinical trial","volume":"67","author":"Hosseinipour","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"526","key":"10.1016\/j.cct.2019.105846_bb0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated assessment of results in clinical trials of cancer treatment","volume":"44","author":"Haybittle","year":"1971","journal-title":"Br. J. Radiol."},{"year":"2000","series-title":"Group Sequential Methods with Applications to Clinical Trials","author":"Jennison","key":"10.1016\/j.cct.2019.105846_bb0095"},{"issue":"18","key":"10.1016\/j.cct.2019.105846_bb0100","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/sim.2151","article-title":"A review of methods for futility stopping based on conditional power","volume":"24","author":"Lachin","year":"2005","journal-title":"Stat. Med."},{"issue":"16","key":"10.1016\/j.cct.2019.105846_bb1000","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419305610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419305610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:46:39Z","timestamp":1761554799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714419305610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":21,"alternative-id":["S1551714419305610"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2019.105846","relation":{},"ISSN":["1551-7144"],"issn-type":[{"type":"print","value":"1551-7144"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim monitoring in a treatment strategy trial with a composite primary endpoint","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2019.105846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105846"}}